269 related articles for article (PubMed ID: 8993085)
21. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study.
Pollack MH; Worthington JJ; Otto MW; Maki KM; Smoller JW; Manfro GG; Rudolph R; Rosenbaum JF
Psychopharmacol Bull; 1996; 32(4):667-70. PubMed ID: 8993089
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.
Mendels J; Johnston R; Mattes J; Riesenberg R
Psychopharmacol Bull; 1993; 29(2):169-74. PubMed ID: 8290661
[TBL] [Abstract][Full Text] [Related]
23. A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treated in general practice.
Trick L; Stanley N; Rigney U; Hindmarch I
J Psychopharmacol; 2004 Jun; 18(2):205-14. PubMed ID: 15260909
[TBL] [Abstract][Full Text] [Related]
24. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
Davidson J; Rothbaum BO; Tucker P; Asnis G; Benattia I; Musgnung JJ
J Clin Psychopharmacol; 2006 Jun; 26(3):259-67. PubMed ID: 16702890
[TBL] [Abstract][Full Text] [Related]
25. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic action lag time and resistance to treatment].
Peretti CS
Encephale; 1999 Jun; 25 Spec No 2():49-54. PubMed ID: 10434159
[TBL] [Abstract][Full Text] [Related]
27. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers.
Barbanoj MJ; Clos S; Romero S; Morte A; Giménez S; Lorenzo JL; Luque A; Dal-Ré R
Neuropsychobiology; 2005; 51(3):134-47. PubMed ID: 15838185
[TBL] [Abstract][Full Text] [Related]
28. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
29. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
Amsterdam JD; Shults J
J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
Thase ME
J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
[TBL] [Abstract][Full Text] [Related]
31. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
[TBL] [Abstract][Full Text] [Related]
32. Venlafaxine in depressed outpatients.
Khan A; Fabre LF; Rudolph R
Psychopharmacol Bull; 1991; 27(2):141-4. PubMed ID: 1924660
[TBL] [Abstract][Full Text] [Related]
33. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
Rudolph RL; Fabre LF; Feighner JP; Rickels K; Entsuah R; Derivan AT
J Clin Psychiatry; 1998 Mar; 59(3):116-22. PubMed ID: 9541154
[TBL] [Abstract][Full Text] [Related]
34. A comparison of venlafaxine, trazodone, and placebo in major depression.
Cunningham LA; Borison RL; Carman JS; Chouinard G; Crowder JE; Diamond BI; Fischer DE; Hearst E
J Clin Psychopharmacol; 1994 Apr; 14(2):99-106. PubMed ID: 8195464
[TBL] [Abstract][Full Text] [Related]
35. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression.
Shrivastava RK; Cohn C; Crowder J; Davidson J; Dunner D; Feighner J; Kiev A; Patrick R
J Clin Psychopharmacol; 1994 Oct; 14(5):322-9. PubMed ID: 7806687
[TBL] [Abstract][Full Text] [Related]
36. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.
Guelfi JD; Ansseau M; Timmerman L; Kørsgaard S;
J Clin Psychopharmacol; 2001 Aug; 21(4):425-31. PubMed ID: 11476127
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of trimipramine and fluoxetine on sleep in geriatric depression.
Wolf R; Dykierek P; Gattaz WF; Maras A; Kohnen R; Dittmann RW; Geuppert M; Riemann D; Berger M
Pharmacopsychiatry; 2001 Mar; 34(2):60-5. PubMed ID: 11302565
[TBL] [Abstract][Full Text] [Related]
38. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
Cunningham LA
Ann Clin Psychiatry; 1997 Sep; 9(3):157-64. PubMed ID: 9339881
[TBL] [Abstract][Full Text] [Related]
39. The role of venlafaxine in rational antidepressant therapy.
Feighner JP
J Clin Psychiatry; 1994 Sep; 55 Suppl A():62-8; discussion 69-70, 98-100. PubMed ID: 7961545
[TBL] [Abstract][Full Text] [Related]
40. Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables.
Kerkhofs M; Rielaert C; de Maertelaer V; Linkowski P; Czarka M; Mendlewicz J
Int Clin Psychopharmacol; 1990 Oct; 5(4):253-60. PubMed ID: 2081896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
